Dr Valentin Fuster, MD, PhD, to Keynote PCNA 20th Annual Symposium
The keynote speaker for the 2014 PCNA Annual Symposium is Valentin Fuster, MD, PhD. Dr Fuster is not only an accomplished physician but also is a distinguished professor and has been honored with numerous awards. In 2012, Dr Fuster received the highest honor given by the American Heart Association: the 2012 Research Achievement Award. He is the only cardiologist to receive the 2 highest gold medal awards and all 4 major research awards from the 4 major cardiovascular organizations. Dr Fuster has ranked among the Top Doctors in the United States for the past 13 years.
Dr Fuster has an extensive number of articles published in journals and has authored various textbooks. Dr Fuster was the lead editor for 2 major cardiovascular textbooks, The Heart and Atherothrombosis and Coronary Artery Disease. Dr Fuster serves The Mount Sinai Medical Center as Physician-in-Chief, as well as Director of Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health. He is also the Richard Gorlin, MD/Heart Research Foundation Professor, Mount Sinai School of Medicine. Dr. Fuster was the President of Science and is now the General Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, Spain and also and Chairman of the SHE Foundation (Science for Health and Education).
Dr Fuster’s keynote opening address is titled “Cardiovascular Disease to Health: Journey of the High Risk Plaque.” He has most recently been the principal investigator in a High Risk Plaque Bioimage initiative, centered at predicting subclinical disease. Dr Fuster’s lifetime achievements have been focused on the prevention of cardiac disease and promotion of cardiovascular health worldwide. The Preventative Cardiovascular Nursing Association is honored to have such a world-renowned physician delivering our keynote address.
Think Cultural for April’s National Minority Health Month
No caption available...Image Tools
The Office of Minority Health (OMH) and partners such as the Centers for Disease Control and Prevention have designated April as National Minority Health Month. The goal is to raise awareness about healthcare disparities that affect racial and ethnic minorities in the United States and profile programs and policies created to reduce these disparities and achieve healthcare equity. A landmark study from the Institute of Medicine titled “Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care” brought this issue to national attention in 2002, http://www.iom.edu/Reports/2002/Unequal-Treatment-Confronting-Racial-and-Ethnic-Disparities-in-Health-Care.aspx. The American College of Cardiology responded by creating the Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes with educational programs and tools to meet the needs of a diverse patient population. One such example is a Spanish-language cardiac rehabilitation video endorsed by PCNA, http://www.cardiosource.org/Lifelong-Learning-and-MOC/Focus-On/credo.aspx.
In 2011, the Journal of the American College of Cardiology issued a White Paper on the Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes with an ultimate goal of providing equitable care and outcomes for all patients, regardless of race, ethnicity, sex, and age. Its authors impress upon the importance of meeting this demand because according to the US Census Bureau projects, by 2042, Hispanic and Latino populations will compose 30% of the population; followed by African Americans at 15%; and, increasingly, large subpopulations of Asians, American Indians, and Alaska Natives, http://www.cardiosource.org/Certified-Education/credo/~/media/Files/Education/credo/credo%20white%20paper_JACC%20pub.ashx.
The American Heart Association’s 2014 Heart Disease and Stroke Statistics compiled information on ethnicity, revealing Mexican Americans to be disproportionally affected by overweight and obesity, whereas blacks have a higher prevalence of high blood pressure, stroke, and heart failure. A greater participation of minorities in research is needed to discern variations in cardiovascular care that may be required. For example, major clinical trials led to guideline-directed medical therapy for heart failure, dictating that the combination of hydralazine and isosorbide dinitrate be recommended for African Americans with New York Heart Association class III to IV heart failure with reduced ejection fraction, http://www.heart.org/HEARTORG/. The ongoing National Institutes of Health–sponsored Multi-ethnic Study of Atherosclerosis addresses this need by actively recruiting research participants of white, black, Hispanic, and Chinese origins, http://mesa-nhlbi.org/.
To guide healthcare professionals on cultural competency, the OMH has created National Standards for Culturally and Linguistically Appropriate Services, communication tools, and online continuing education available free of charge. “Culturally Competent Nursing Care: A Cornerstone of Caring” is a free online educational program for nurses and social workers created to promote health equity. Comparable programs are available for physicians, first responders, and those in the dental field.
The National Partnership for Action to End Health Care Disparities, in collaboration with the OMH and the Department of Health and Human Services, has created a toolkit for community action to mobilize organizations and individuals to help create a nation in which all persons can reach their full health potential. Just taking these 5 steps can help to make a difference:
1. Increase awareness about health disparities (ie, via letters to the editor, contacting local television media, and speaking at health fairs).
2. Become a leader for addressing health disparities (ie, serve as a mentor to those persons and organizations wishing to adopt a healthy lifestyle).
3. Support healthy and safe behaviors in your community (ie, promote the First Lady’s “Choose to Move” campaign and the“President’s Challenge”).
4. Improve access to healthcare (ie, assist with free health screenings or facilitate use of translation services for health information).
5. Create healthy neighborhoods (ie, participate in PCNA’s Advocacy Central to request legislative change on healthcare issues), http://minorityhealth.hhs.gov/npa/files/Plans/Toolkit/NPA_Toolkit.pdf.
In our increasingly racially and ethnically diverse homes and workplace settings, nurses taking steps to “Think Cultural” can positively impact the health of families, neighborhoods, and communities, https://www.thinkculturalhealth.hhs.gov/.
Join Us in Atlanta for a Pharmacology Preconference
In 2014, for the first time, the Preventive Cardiovascular Nurses Association (PCNA) will be hosting a Pharmacology Preconference on the day before the PCNA annual symposium. This inaugural program, directed by PCNA board member Joanna Sikkema, DNP, MSN, ANP-BC, FAHA, FPCNA, is scheduled for Wednesday, April 9, from 12:30 to 5:30 PM and will cover the following topics in depth:
* Hypertension: Dr Sikkema
* Unintended Cardiovascular Effects of Mood, Sleep, and Pain Medications: Kevin B. Sneed, PharmD
* Antiplatelet Therapy: Lynne Braun, PhD, CNP, CLS, FAHA, FPCNA, FAAN
* Anticoagulation: Janet Long, MSN, ACNP, CLS, FAHA, FPCNA
* Case Studies: Panel with All Faculty
This program was designed in particular to help meet the needs of advanced practice nurses in fulfillment of their required pharmacology continuing education credits. Learners will be forwarded key reference materials 6 weeks before the conference (by March 1). These precourse materials will provide background information—links to national prescribing guidelines and key publications of randomized trials of novel anticoagulants and antiplatelet agents. Registrants are required to complete and submit a self-assessment before the live meeting (no minimum score required, to enhance the learning experience, for learner information only). This will help prepare learners for a case-based clinical approach at the conference. After attendance at the April 9 program, learners will complete a postcourse assessment and a CE evaluation to claim a total of 7 hours of CE credit, all of which is pharmacology content. The 2014 pharmacology preconference is open to those attending the 2014 annual symposium as well as those who choose to attend the preconference only. We believe that assembling 3 advanced practice nurse thought leaders with deep and broad experience in cardiovascular disease (CVD) management with our Pharm D colleague Kevin Sneed will provide an unbeatably high-quality program. Please feel free to contact the PCNA office with any questions about this session.
Note: Preceding the preconference, an optional, complimentary non-CE product theater lunch will be held at 11:15 AM. Preconference registrants are invited to attend. Further information will follow.
Learning objectives for the 2014 PCNA Pharmacology Preconference are as follows.
At the conclusion, the learner will:
* Summarize the findings of 2 landmark clinical trials that help guide the management of hypertension in the patient with diabetes.
* Define the concept of “compelling indications” in the choice of pharmacologic agent in the management of hypertension.
* Summarize the indications for angiotensin-converting enzyme, angiotensin receptor blocker, and β-blocker therapy in secondary prevention of CVD.
* Identify the recommendations for monitoring renal function and potassium levels in patients with chronic kidney disease who are prescribed angiotensin-converting enzymes or ARBs.
* Identify the role of advanced age in determining the starting dose(s) and titration of various antihypertensive agents.
* Summarize the evidence regarding the safety of selective serotonin reuptake inhibitor antidepressants in patients with coronary heart disease.
* Outline the role of CVD history and CVD risk assessment in safe prescribing of pharmacologic agents for mild to moderate pain relief.
* List the factors that may increase the risk for cardiac side effects (including cardiac arrhythmias) associated with the administration of nonbenzodiazepine hypnotics.
* Identify the source of evidence-based guidelines for antiplatelet therapy in the post-percutaneous coronary intervention patient.
* Cite recommendations for low-dose aspirin as primary prevention of myocardial infarction and stroke.
* Contrast the recommendations for antiplatelet therapy for patients after drug-eluting stent versus bare metal stent.
* Define the concept of platelet reactivity.
* Quantify the impact of nonadherence to antiplatelet therapy on the occurrence of in-stent thrombosis.
* Identify the factor(s) in the coagulation cascade on which warfarin, dabigatran, rivaroxaban, and apixaban exert their respective anticoagulant effects (precourse work).
* Identify 2 sources for evidence-based guidelines for antithrombotic therapy in the reduction of cardioembolic risk in the patient with nonvalvular atrial fibrillation.
* List the major finding from each of the landmark clinical trials of new anticoagulant agents (Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY), Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF (ROCKET-AF), and Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE).
* Define the impact of renal function and patient age on the choice of anticoagulant agent.
* Distinguish which of the novel anticoagulants are indicated for treatment of venous thromboembolism and deep vein thrombosis prophylaxis in the patient undergoing orthopedic surgery.